1.Hucke F., Sieghart W., Schoniger-Hekele M., Peck-Radosavljevic M., Muller C. Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? Wien Klin Wochenschr 2011.2.Schoniger-Hekele M., Muller C., Kutilek M., Oesterreicher C., Ferenci P., Gangl A. Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation. Eur J Gastroenterol Hepatol 2000; 12: 941-48.3.Llovet J.M., Di Bisceglie A.M., Bruix J., et al. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. J Natl Cancer Inst 2008; 100: 698-711.4.Forner A., Reig M.E., Rodriguez de Lope C., Bruix J. Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects. Semin Liver Dis 2010; 30: 61-74.5.Peck-Radosavljevic M. "Back to basics: Staging and Prognosis in HCC for Medical Oncologist". J Hepatol 2011.6.Bruix J., Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-22.7.Brunt E.M., Gores G. "Pardon the interruption": comments on the International Liver Cancer Association Fourth Annual Conference, 2010. Is there really no role for liver biopsy interpretation in liver cancer? Hepatology 2011; 53: 721-22.8.Peck-Radosavljevic M. Imaging and early diagnosis of hepatocellular carcinoma. Minerva Gastroenterol Dietol 2011; 57: 273-86.9.Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.10.Sangiovanni A., Manini M.A., lavarone M., et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010; 59: 638-44.11.Lencioni R., Llovet J.M. Modified RECIST (mRE-CIST) Assessment for Hepatocellular Carcinoma. Semin Liver Dis 2010; 30: 52-60.12.Bruix J., Castells A., Bosch J., Feu F., et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: 1018-22.13.Poon R.T., Fan S.T., Lo C.M., Liu C.L., Wong J. Longterm survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002; 235: 373-82.14.Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis [see comments]. N Engl J Med 1996; 334: 693-99.15.Yao F.Y., Xiao L., Bass N.M., et al. Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF-Expanded Criteria Based on Preoperative Imaging. Am J Transplant 2007; 7: 2587-96.16.Mazzaferro V., Llovet J.M., Miceli R., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.17.Lu D.S., Yu N.C., Raman S.S., et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005; 41: 1130-37.18.Belghiti J., Cortes A., Abdalla E.K., et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003; 238: 885-92; discussion 892-83.19.Graziadei I.W., Sandmueller H., Waldenberger P., et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9: 557-63.20.Forner A., Bruix J. To expand or not to expand the criteria for hepatocellular carcinoma transplantation: is downstaging the answer? Gastroenterology 2009; 137: 375-76.21.Freeman R.B., Jr. Model for end-stage liver disease (MELD) for liver allocation: a 5-year score card. Hepatology 2008; 47: 1052-57.22.Neuberger J. Liver allocation for patients with hepatocellular carcinoma. Liver Transpl 2010; 16: 249-51.23.Todo S., Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004; 240: 451-9; discussion 459-61.24.Taniguchi M., Kim S.R., Imoto S., et al. Longterm outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1997-2002.25.Lin S.M., Lin C.J., Lin C.C., et al. Radio frequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004; 127: 1714-23.26.Cho Y.K., Kim J.K., Kim M.Y., Rhim H., Han J.K. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49: 453-59.27.Chen M.S., Li J.Q., Zheng Y., et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-28.28.Livraghi T., Meloni F., Di Stasi M., et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008; 47: 82-9.29.Lammer J., Malagari K., Vogl T., et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.30.Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet. 2012; 1245-55.31.Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-42.32.Peck-Radosavljevic M., Greten T.F., Lammer J. et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2010; 22: 391-98.33.Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.